Cargando…
The role of MSCs and CAR-MSCs in cellular immunotherapy
Chimeric antigen receptors (CARs) are widely used by T cells (CAR-T cells), natural killer cells dendritic cells and macrophages, and they are of great importance in cellular immunotherapy. However, the use of CAR-related products faces several challenges, including the poor persistence of cells car...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391838/ https://www.ncbi.nlm.nih.gov/pubmed/37528472 http://dx.doi.org/10.1186/s12964-023-01191-4 |
_version_ | 1785082808925945856 |
---|---|
author | Yan, Lun Li, Jing Zhang, Cheng |
author_facet | Yan, Lun Li, Jing Zhang, Cheng |
author_sort | Yan, Lun |
collection | PubMed |
description | Chimeric antigen receptors (CARs) are widely used by T cells (CAR-T cells), natural killer cells dendritic cells and macrophages, and they are of great importance in cellular immunotherapy. However, the use of CAR-related products faces several challenges, including the poor persistence of cells carrying CARs, cell dysfunction or exhaustion, relapse of disease, immune effector cell-associated neurotoxicity syndrome, cytokine release syndrome, low efficacy against solid tumors and immunosuppression by the tumor microenvironment. Another important cell therapy regimen involves mesenchymal stem cells (MSCs). Recent studies have shown that MSCs can improve the anticancer functions of CAR-related products. CAR-MSCs can overcome the flaws of cellular immunotherapy. Thus, MSCs can be used as a biological vehicle for CARs. In this review, we first discuss the characteristics and immunomodulatory functions of MSCs. Then, the role of MSCs as a source of exosomes, including the characteristics of MSC-derived exosomes and their immunomodulatory functions, is discussed. The role of MSCs in CAR-related products, CAR-related product-derived exosomes and the effect of MSCs on CAR-related products are reviewed. Finally, the use of MSCs as CAR vehicles is discussed. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-023-01191-4. |
format | Online Article Text |
id | pubmed-10391838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103918382023-08-02 The role of MSCs and CAR-MSCs in cellular immunotherapy Yan, Lun Li, Jing Zhang, Cheng Cell Commun Signal Review Chimeric antigen receptors (CARs) are widely used by T cells (CAR-T cells), natural killer cells dendritic cells and macrophages, and they are of great importance in cellular immunotherapy. However, the use of CAR-related products faces several challenges, including the poor persistence of cells carrying CARs, cell dysfunction or exhaustion, relapse of disease, immune effector cell-associated neurotoxicity syndrome, cytokine release syndrome, low efficacy against solid tumors and immunosuppression by the tumor microenvironment. Another important cell therapy regimen involves mesenchymal stem cells (MSCs). Recent studies have shown that MSCs can improve the anticancer functions of CAR-related products. CAR-MSCs can overcome the flaws of cellular immunotherapy. Thus, MSCs can be used as a biological vehicle for CARs. In this review, we first discuss the characteristics and immunomodulatory functions of MSCs. Then, the role of MSCs as a source of exosomes, including the characteristics of MSC-derived exosomes and their immunomodulatory functions, is discussed. The role of MSCs in CAR-related products, CAR-related product-derived exosomes and the effect of MSCs on CAR-related products are reviewed. Finally, the use of MSCs as CAR vehicles is discussed. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-023-01191-4. BioMed Central 2023-08-01 /pmc/articles/PMC10391838/ /pubmed/37528472 http://dx.doi.org/10.1186/s12964-023-01191-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Yan, Lun Li, Jing Zhang, Cheng The role of MSCs and CAR-MSCs in cellular immunotherapy |
title | The role of MSCs and CAR-MSCs in cellular immunotherapy |
title_full | The role of MSCs and CAR-MSCs in cellular immunotherapy |
title_fullStr | The role of MSCs and CAR-MSCs in cellular immunotherapy |
title_full_unstemmed | The role of MSCs and CAR-MSCs in cellular immunotherapy |
title_short | The role of MSCs and CAR-MSCs in cellular immunotherapy |
title_sort | role of mscs and car-mscs in cellular immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391838/ https://www.ncbi.nlm.nih.gov/pubmed/37528472 http://dx.doi.org/10.1186/s12964-023-01191-4 |
work_keys_str_mv | AT yanlun theroleofmscsandcarmscsincellularimmunotherapy AT lijing theroleofmscsandcarmscsincellularimmunotherapy AT zhangcheng theroleofmscsandcarmscsincellularimmunotherapy AT yanlun roleofmscsandcarmscsincellularimmunotherapy AT lijing roleofmscsandcarmscsincellularimmunotherapy AT zhangcheng roleofmscsandcarmscsincellularimmunotherapy |